Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.45 |
| ▸ | HRH1 | P35367 | 3/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DTYMK | P23919 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909121 | 0.94 | NPC1 (0.47) | SMN1; SMN2LMNANPC1NR2F2HTT | |
| SCHEMBL23914934 | 0.90 | LMNA (0.51) | SMN1; SMN2LMNANPC1NR2F2HTT | |
| SCHEMBL23914926 | 0.90 | MAPT (0.48) | SMN1; SMN2LMNANPC1NR2F2HTT | |
| SCHEMBL23966858 | 0.88 | LMNA (0.46) | SMN1; SMN2LMNANPC1NR2F2HTT | |
| SCHEMBL23908931 | 0.84 | NPC1 (0.47) | SMN1; SMN2LMNANPC1NR2F2HTT | |
| SCHEMBL23913676 | 0.84 | MAPT (0.53) | SMN1; SMN2LMNANPC1NR2F2HTT | |
| SCHEMBL2995095 | 0.84 | ADRA1A (0.69) | SMN1; SMN2LMNAADRA1AHRH1ADRA1B | |
| SCHEMBL23909085 | 0.82 | MAPT (0.58) | MAPTPOLBADRA1AHRH1ADRA1B | |
| SCHEMBL2820393 | 0.81 | ADRA1A (0.68) | SMN1; SMN2LMNAADRA1AHRH1ADRA1B | |
| SCHEMBL23915443 | 0.81 | MAPT (0.51) | SMN1; SMN2LMNANPC1NR2F2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | SMN1; SMN2 2920/4885LMNA 449/4885NPC1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.